Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong · Delayed Price · Currency is HKD 538.00
+5.00 (0.94%)
Aug 21, 2026, 4:08 PM HKT
HKG:6990 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,086 | 2,058 | 1,933 | 1,540 | 803.93 | 32.32 | |
Revenue Growth | 38.99% | 6.46% | 25.48% | 91.62% | 2387.26% | - |
Cost of Revenue | 530.12 | 579.14 | 659.39 | 781.31 | 277.14 | 23.07 |
Gross Profit | 1,556 | 1,479 | 1,274 | 759.19 | 526.8 | 9.25 |
Selling, General & Admin | 871.7 | 653.97 | 346.03 | 201.41 | 93.03 | 90.98 |
Research & Development | 1,477 | 1,320 | 1,206 | 1,031 | 845.98 | 727.67 |
Other Operating Expenses | -795.57 | -75.29 | 0.72 | -19.49 | -18.27 | -14.16 |
Operating Expenses | 1,553 | 1,898 | 1,553 | 1,213 | 920.75 | 804.49 |
Operating Income | 2.99 | -419.57 | -279.22 | -453.7 | -393.95 | -795.24 |
Interest Expense | -5.21 | -6.16 | -3.8 | -84.31 | -148.81 | -112.59 |
Interest & Investment Income | 63.54 | 63.54 | 34.18 | 45.19 | 1.42 | 0.81 |
Currency Exchange Gain (Loss) | -46.27 | -46.27 | 17.79 | 16.09 | -31.94 | 16.88 |
EBT Excluding Unusual Items | 15.05 | -408.46 | -231.05 | -476.74 | -573.3 | -890.15 |
Gain (Loss) on Sale of Investments | 24.13 | 24.13 | 21.55 | 10.53 | 0.51 | 0.36 |
Gain (Loss) on Sale of Assets | -0.12 | -0.12 | -0.15 | -1.49 | 5.42 | -0.01 |
Other Unusual Items | 28.67 | 28.67 | 67.1 | - | - | - |
Pretax Income | 67.73 | -355.78 | -142.55 | -467.69 | -567.36 | -889.8 |
Income Tax Expense | -83.48 | 26.19 | 124.22 | 106.44 | 48.74 | - |
Net Income | 151.21 | -381.97 | -266.77 | -574.13 | -616.1 | -889.8 |
Preferred Dividends & Other Adjustments | - | - | - | -51.93 | -68 | -67.25 |
Net Income to Common | 151.21 | -381.97 | -266.77 | -522.21 | -548.1 | -822.55 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 233 | 231 | 222 | 184 | 96 | 92 |
Shares Outstanding (Diluted) | 233 | 231 | 222 | 184 | 96 | 92 |
Shares Change | 3.43% | 4.01% | 20.70% | 92.24% | 3.31% | - |
EPS (Basic) | 0.65 | -1.66 | -1.20 | -2.84 | -5.74 | -8.90 |
EPS (Diluted) | 0.65 | -1.66 | -1.20 | -2.84 | -5.74 | -8.90 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 420.8 | -305.99 | -507.23 | -21.42 | -304.51 | -580.03 |
Free Cash Flow Per Share | 1.80 | -1.33 | -2.29 | -0.12 | -3.19 | -6.27 |
Gross Margin | 74.59% | 71.86% | 65.89% | 49.28% | 65.53% | 28.62% |
Operating Margin | 0.14% | -20.39% | -14.45% | -29.45% | -49.00% | -2460.37% |
Profit Margin | 7.25% | -18.56% | -13.80% | -33.90% | -68.18% | -2544.86% |
Free Cash Flow Margin | 20.17% | -14.87% | -26.24% | -1.39% | -37.88% | -1794.52% |
EBITDA | 58.8 | -364.78 | -230.93 | -419.78 | -367.99 | -775.61 |
EBITDA Margin | 2.82% | -17.73% | -11.95% | -27.25% | -45.77% | - |
D&A For EBITDA | 55.81 | 54.79 | 48.29 | 33.92 | 25.97 | 19.63 |
EBIT | 2.99 | -419.57 | -279.22 | -453.7 | -393.95 | -795.24 |
EBIT Margin | 0.14% | -20.39% | -14.44% | -29.45% | -49.00% | - |